Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
Status:
RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to learn if the study drug DMB-I (INN: Latrepirdine) works to treat Alzheimer type dementia in adults. It will also learn about the safety of DMB-I (INN: Latrepirdine).
The main questions it aims to answer are:
* Does DMB-I improve cognitive functions in patients with dementia associated with Alzheimer's disease, and how sigificant the improvement is?
* What medical problems do participants have when taking DMB-I? Researchers will compare DMB-I to a placebo (a look-alike substance that contains no drug) to see if the study drug works to treat Alzheimer type dementia.
* Is DMB-I effective and safe when taken long-term?
Participants will:
Take the study drug or a placebo (with or without Akatinol Memantine) every day for 26 weeks at Stage 1 of the study, and take the study drug (with or without Akatinol Memantine) every day for 26 weeks at Stage 2 of the study.
Visit the clinic 13 times for checkups and tests Keep a diary of their symptoms